08:30 - 09:25  Registration and Coffee

09:25 - 09:30  Welcome

09:30 - 11:00  What’s new in NETs? ENETS guidelines update (new recommendations applied to interactive cases), UK epidemiology and genetics
   Chairs: Andrea Frilling (London) & Martin Weickert (Coventry)

09:30  Midgut NETs – Mohid Khan (Cardiff)
09:50  Pancreatic NETs - Judith Cave (Southampton)
10:10  Bronchial NETs - Wasat Mansoor (Manchester)
10:30  Update on national incidence data from Public Health England (PHE) - John Ramage (London)
10:45  Where NETs fit in with the 100,000 genome project – Clare Craig (London)

11:00 - 11:30  Coffee, Exhibition and Posters

11:30 - 12:45  Management of Phaeochromocytoma/Paraganglioma
   Chairs: Maralyn Druce (London) & David Scott-Coombes (Cardiff)
11:30  Clinician viewpoint – Simon Aylwin (London)
11:55  Special considerations in the management of patients with familial Phaeochromocytoma/Paraganglioma syndromes - Scott Akker (London)
12:20  Imaging viewpoint - Shaunak Navalkissoor (London)

12:45 - 13:00  AGM

13:00 - 14:00  Lunch, Exhibition & Posters

14:00 - 14:45  Debate: This house believes management of patients with NETs should be undertaken by.....
   Chair: Christos Toumpanakis (London)

14:00  Oncologists
   Nick Reed (Glasgow)
14:05  Gastroenterologists
   Martyn Caplin (London)
14:10  Endocrinologists
   Ashley Grossman (Oxford)
14:15  Discussion with audience participation

14:45 - 15:30  Open clinical session
   Chairs: Barbara King (London) & Nickie Jervis (London)

14:45  Survey of the Somatostatin Analogue use in the UK
   Mike Tadman (Oxford)
15:00  An exploration of psychological symptoms in Carcinoid Syndrome
   Liz Friend (Basingstoke)

14:45 - 15:30  Translational Science Session
   Chair: Chrissie Thirlwell (London)

14:45  Whole-exome sequencing (WES) of samples from patients with advanced pancreatic neuroendocrine tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies
   Jorge Barriuso (Manchester)
15:05  Immunotherapy in solid tumours, determination of immune-response and where this might lead in NETs
   Christian Ottensmeier (Southampton)

15:30 - 16:00  Coffee, Exhibition and Posters

16:00 - 16:30  Oral Communications
   Chairs: John Ayuk (Birmingham) & Mark Pritchard (Liverpool)

16:00  Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis – Malcolm Boyce (London)
16:10  Tumour Size is Not a Reliable Criterion for Management of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of a Large, Multi-Centre, Operative Cohort – Logan Mills (Coventry)
16:20  Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period – Martin Caplin (Slough)

16:30 - 17:00  International Speaker & Trials update
   Chair: Tim Meyer (London)

16:30  NET therapy on the horizon - evaluating the current evidence - Kjell Öberg (Uppsala, Sweden)
17:00  Trials update – Juan Valle (Manchester)

17:20 - 17:30  Prize giving & closing
17:30  Wine & cheese